FDA Defends Drug Approval Decisions Amid Criticism Over Experimental Treatments

The U.S. Food and Drug Administration is defending its recent decisions on experimental drug approvals after facing growing criticism from pharmaceutical companies and outside experts.

In an unusual move, a senior FDA official held a call with reporters to explain the agency’s decision to require additional clinical testing for a gene therapy developed by biotechnology company UniQure to treat Huntington’s disease.

Patients and the company had hoped the therapy could move directly into the FDA’s review process based on existing data. Instead, regulators asked the company to conduct another clinical trial before applying for approval.

Huntington’s disease is a fatal neurodegenerative disorder that currently has no cure, and advocates say potential treatments are urgently needed.

During the call, the FDA official defended the agency’s position, saying placebo-controlled trials are necessary to ensure treatments are both safe and effective. The official also pushed back on claims that the FDA was requiring an extensive “sham surgery” as part of the trial design.

The therapy being studied is delivered through a one-time infusion directly into the brain during an eight- to ten-hour surgical procedure. Regulators say any placebo procedure used for comparison would involve significantly less time under anesthesia.

The decision is part of a broader debate about whether the FDA has recently shifted its standards for approving new drugs.

Several biotechnology companies have argued that recent regulatory decisions contradict earlier guidance from the agency, potentially slowing the approval process for new treatments.

The FDA has also faced criticism in recent months for decisions involving other experimental therapies, including rare disease treatments and an mRNA flu vaccine developed by Moderna.

Agency officials say the additional requirements are meant to ensure new medicines are backed by strong scientific evidence before reaching patients.

Explore: NBCPalmSprings.com, where we are connecting the Valley.